David P Goldman

US Patent:

6762294, Jul 13, 2004

Filed:

Aug 15, 2001

Appl. No.:

09/930589

Inventors:

David Goldman - Potomac MD
Nakao Iwata - Aichi, JP
Marc A. Schuckit - Del Mar CA

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07H 2104

US Classification:

536 235, 435 6

Abstract:

Compositions and methods based on a polymorphism in the gene encoding the 6 subunit of the human GABA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.

US Patent:

7273699, Sep 25, 2007

Filed:

Jul 25, 2002

Appl. No.:

10/206561

Inventors:

Robert H. Lipsky - Kensington MD, US
Chiara Mazzanti - Washington DC, US
David Goldman - Potomac MD, US

Assignee:

The United States of America as Represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 6, 435 912

Abstract:

Sequence variations, such as polymorphisms, are detected by detecting differences between or among melting profiles of plural nucleic acids. Melting profiles are produced by observing the nucleic acids during a temperature change over a period of time. If the nucleic acids are diluted into solutions for analysis, the nucleic acid concentrations between or among the solutions can be substantially the same. The melting profiles and sequence variation can be used to identify changes in a wild-type nucleic acid sequence, such as a single-nucleotide polymorphism (SNP), a small insertion or deletion, or a small inversion.

US Patent:

8635571, Jan 21, 2014

Filed:

Oct 19, 2012

Appl. No.:

13/656361

Inventors:

David Samuel Goldman - Washington DC, US

Assignee:

Altera Corporation - San Jose CA

International Classification:

G06F 17/50

US Classification:

716117, 716116

Abstract:

This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for transmitting and integrating an intellectual property (IP) block with another user's design. The IP developer can design the IP block to include both a secret portion and a public portion. The IP block developer can send or otherwise provide the IP block to another IP user without disclosing the functional description of the secret portion of the IP block. In some implementations, the IP developer provides the public portion to the IP user at the register-transfer-level (RTL) level, as a hardware description language (HDL)-implemented design, or as a synthesizable netlist. In some implementations, the IP developer provides the secret portion of the IP block to the user in the form of programming bits without providing an HDL, RTL, or netlist implementation of the secret portion.

US Patent:

20030100476, May 29, 2003

Filed:

May 10, 2002

Appl. No.:

10/144000

Inventors:

Daniel Weinberger - Washington DC, US
Michael Egan - Chevy Chase MD, US
Terry Goldberg - Bethesda MD, US
Joseph Callicott - Bethesda MD, US
David Goldman - Potomac MD, US

International Classification:

A61K031/00
C12Q001/68

US Classification:

514/001000, 435/006000

Abstract:

The invention provides a method of detecting impaired prefrontal cognitive function in an individual by determining the individual's COMT genotype, and associating a high activity Val allele with impaired prefrontal cognitive function (and a low activity Met allele with enhanced prefrontal cognitive function).

US Patent:

20050014170, Jan 20, 2005

Filed:

Feb 27, 2004

Appl. No.:

10/789169

Inventors:

Daniel Weinberger - Washington DC, US
Michael Egan - Chevy Chase MD, US
Bhaskar Kolachana - Oakton VA, US
David Goldman - Potomac MD, US
Joseph Callicott - Bethesda MD, US
Terry Goldberg - Bethesda MD, US

International Classification:

C12Q001/68

US Classification:

435006000

Abstract:

The invention is related to the discovery that a met66val polymorphism in the gene for brain-derived neurotrophic factor (BDNF) is correlated with hippocampal function and verbal memory and risk for neuropsychiatric disorders such as schizophrenia.

US Patent:

20060166264, Jul 27, 2006

Filed:

Mar 31, 2006

Appl. No.:

11/395043

Inventors:

Daniel Weinberger - Washington DC, US
Michael Egan - Chevy Chase MD, US
Terry Goldberg - Bethesda MD, US
Joseph Callicott - Bethesda MD, US
David Goldman - Potomac MD, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

The invention provides a method of detecting impaired prefrontal cognitive function in an individual by determining the individual's COMT genotype, and associating a high activity Val allele with impaired prefrontal cognitive function (and a low activity Met allele with enhanced prefrontal cognitive function).

US Patent:

20120227026, Sep 6, 2012

Filed:

Mar 3, 2011

Appl. No.:

13/040255

Inventors:

David Samuel Goldman - Washington DC, US
Mark Bourgeault - Mississauga, CA
Vaughn Betz - Toronto, CA
Alan Louis Herrmann - Sunnyvale CA, US

Assignee:

Altera Corporation - San Jose CA

International Classification:

G06F 17/50

US Classification:

716128

Abstract:

A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.

US Patent:

45088209, Apr 2, 1985

Filed:

Feb 27, 1984

Appl. No.:

6/582862

Inventors:

Carl R. Merril - Rockville MD
David Goldman - Gaithersburg MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C12Q 129
C12Q 116
G01T 100

US Classification:

435 29

Abstract:

The invention provides an assay method for cellular and extracellular protein biodynamics comprising the use of radiochemical techniques in combination with high resolution protein separation procedures and recently developed silver stain techniques, to assess turnover of polypeptides over time. Quenching of polypeptide radiolables in silver stained gels is obviated by the use of. sup. 14 C-labelled amino acids as precursors.